

Singular Health Group Ltd: SHG

ASX Announcement

14th February 2024

\$4.05m Capital Raising

- Singular has received firm commitments to raise approximately \$4.05m via a single tranche placement.
- Proceeds to be used to accelerate United States commercialisation including sales and marketing, building on the recent success of enterprise sales in the US, development of initial Medical Artificial Intelligence (AI)-in-the-Cloud system and working capital requirements.

14 February 2024 – Medical technology company Singular Health Group Ltd (ASX: SHG) (“Singular Health”, or “the Company”) is pleased to announce it has received firm commitments to raise approximately \$4.05m from institutional, sophisticated and professional investors via the issue of 36,843,111 fully paid ordinary shares at \$0.11 per share (“Placement”), a 9.5% discount to a 20 day VWAP of A\$0.121 as at 8 February 2024.

Since listing in early 2021, Singular Health has gained all the required certifications and regulatory clearances, including a US FDA510(k) diagnostic clearance, to commercialize the technology in the main USA market and after appointing a US Master Distributor in 2023, the Company has recently seen significant early traction with enterprise sales to Veterans organisations and US Universities over the past month.

The funds from the Placement will be used to accelerate the Company’s United States commercialisation efforts and seeks to capitalise on the recent sales traction in the United States. The Company will also utilise some of the Placement funds to progress development of development of an initial Medical Artificial Intelligence (AI)-in-the-Cloud system.

The Placement will be completed utilising the Company’s existing Listing Rule 7.1 and 7.1A placement capacity, with settlement of the Placement scheduled for Wednesday 21 February 2024.

Shaw and Partners acted as Lead Manager to the Placement.

Singular Health’s Managing Director, Denning Chong, commented on the Placement, saying:

“We would like to thank all of the Placement participants for their support of Singular Health. Singular Health has a very exciting period ahead and the renewed balance sheet position is important for the Company as it seeks to achieve its ambitions in the US.

“We would also like to thank Shaw and Partners as Lead Manager, to have a company with such a strong reputation and market presence support the capital raising is further vindication of the pathway we are on and we look forward to a long relationship.”

The Placement will be completed via the issue of 21,166,630 million shares under the Company’s existing Listing Rule 7.1 placement capacity, and 15,676,481 million shares under the Company’s existing Listing Rule 7.1A placement capacity. The Lead Manager or their nominees will also be issued 8.5m broker options (\$0.15, 3-year expiry) subject to shareholder approval, which will be sought as soon as practicable by the Company.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Corporations Act**") that:

1. the Company on 9 February 2024 issued 15,454,545 Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
3. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. sections 674 and 674A of the Corporations Act; and
4. as at the date of this notice, there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary support@singular.health

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health’s 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced manufacturing including 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices.

To learn more, visit: <https://www.singular.health> and <https://investors.singular.health/>

For personal use only